Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences?
Learning Objectives After completing this course, the reader will be able to: Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combinati...
Uloženo v:
| Vydáno v: | The oncologist (Dayton, Ohio) Ročník 17; číslo 12; s. 1534 - 1540 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Durham, NC, USA
AlphaMed Press
01.12.2012
|
| Témata: | |
| ISSN: | 1083-7159, 1549-490X, 1549-490X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Learning Objectives
After completing this course, the reader will be able to:
Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combination or sequentially following pre‐existing renal damage.
Describe and quantify the risk of chronic kidney disease in patients treated for ovarian cancer.
This article is available for continuing medical education credit at CME.TheOncologist.com
Background and Objective.
Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum‐ and taxane‐based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long‐term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions.
Patients and Methods.
Fifty‐six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997–2010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002–2010. Patients were diagnosed with CKD if they had an estimated GFR <60 mL/minute per 1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines.
Results.
Thirteen patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy.
Conclusions.
CKD is emerging as a potential long‐term consequence of current chemotherapy for recurrent ovarian cancer.
摘要
背景与目的. 卵巢癌通常在诊断时疾病就已处于晚期，大多数患者接受手术序贯基于铂类或紫杉类的化疗。初始临床缓解后大多数患者会复发，从而需要接受其他治疗，这些治疗不仅包括铂类和紫杉类，而且包括聚乙二醇脂质体多柔比星 （PLD）、吉西他滨和拓扑替康，以及新近使用的可能延长生存期的贝伐珠单抗。特别是PLD已被我们小组进行了广泛的研究，得出了令人鼓舞的治疗结果。然而，我们在因复发性卵巢癌接受长期治疗的患者中观察到了发生慢性肾脏疾病（CKD）的病例。为了明确CKD的发生频率和相关因素，我们在2个机构进行了一项回顾性分析。
患者与方法. 56例在纽约大学癌症研究所接受治疗的连续入组的复发性卵巢癌患者被用来评估1997 ˜ 2010年肾脏疾病的发生情况。在Shaare Zedek医学中心，73例连续入组的卵巢癌患者被用来评估2002 ˜ 2010年肾脏疾病的发生情况。如果估算的肾小球滤过率（eGFR）< 60 mL/min/1.73 m2且持续时间> 3个月，并依据美国肾脏病基金会指南进行分期，患者诊断为CKD。
结果. 13例（23%）患者发生了分期≥3的CKD。3例患者肾活检显示有血栓性微血管病。
结论. CKD是目前接受化疗治疗的复发性卵巢癌患者潜在的长期并发症。
A retrospective review at two institutions was conducted to document the frequency and contributing factors to the emergence of chronic kidney disease among patients receiving long‐term treatment for recurrent ovarian cancer. |
|---|---|
| AbstractList | Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long-term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions.BACKGROUND AND OBJECTIVEOvarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long-term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions.Fifty-six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997-2010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002-2010. Patients were diagnosed with CKD if they had an estimated GFR <60 mL/minute per 1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines.PATIENTS AND METHODSFifty-six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997-2010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002-2010. Patients were diagnosed with CKD if they had an estimated GFR <60 mL/minute per 1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines.Thirteen patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy.RESULTSThirteen patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy.CKD is emerging as a potential long-term consequence of current chemotherapy for recurrent ovarian cancer.CONCLUSIONSCKD is emerging as a potential long-term consequence of current chemotherapy for recurrent ovarian cancer. A retrospective review at two institutions was conducted to document the frequency and contributing factors to the emergence of chronic kidney disease among patients receiving long-term treatment for recurrent ovarian cancer. Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long-term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions. Fifty-six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997-2010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002-2010. Patients were diagnosed with CKD if they had an estimated GFR <60 mL/minute per 1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines. Thirteen patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy. CKD is emerging as a potential long-term consequence of current chemotherapy for recurrent ovarian cancer. Learning Objectives After completing this course, the reader will be able to: Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combination or sequentially following pre‐existing renal damage. Describe and quantify the risk of chronic kidney disease in patients treated for ovarian cancer. This article is available for continuing medical education credit at CME.TheOncologist.com Background and Objective. Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum‐ and taxane‐based chemotherapy. After initial clinical remission, the majority recur, leading to additional treatments, including not only platinums and taxanes but also pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more recently, bevacizumab, which may extend survival times. PLD, in particular, has been extensively studied by our group, with encouraging therapeutic results. We, however, observed instances of chronic kidney disease (CKD) developing among patients who received long‐term treatment for recurrent ovarian cancer. To document the frequency and contributing factors to the emergence of CKD, we initiated a retrospective review at two institutions. Patients and Methods. Fifty‐six consecutive patients with recurrent ovarian cancer receiving treatment at New York University Cancer Institute were reviewed for the presence of renal disease in 1997–2010. At Shaare Zedek Medical Center, 73 consecutive patients with ovarian cancer were reviewed in 2002–2010. Patients were diagnosed with CKD if they had an estimated GFR <60 mL/minute per 1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines. Results. Thirteen patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies performed that showed thrombotic microangiopathy. Conclusions. CKD is emerging as a potential long‐term consequence of current chemotherapy for recurrent ovarian cancer. 摘要 背景与目的. 卵巢癌通常在诊断时疾病就已处于晚期，大多数患者接受手术序贯基于铂类或紫杉类的化疗。初始临床缓解后大多数患者会复发，从而需要接受其他治疗，这些治疗不仅包括铂类和紫杉类，而且包括聚乙二醇脂质体多柔比星 （PLD）、吉西他滨和拓扑替康，以及新近使用的可能延长生存期的贝伐珠单抗。特别是PLD已被我们小组进行了广泛的研究，得出了令人鼓舞的治疗结果。然而，我们在因复发性卵巢癌接受长期治疗的患者中观察到了发生慢性肾脏疾病（CKD）的病例。为了明确CKD的发生频率和相关因素，我们在2个机构进行了一项回顾性分析。 患者与方法. 56例在纽约大学癌症研究所接受治疗的连续入组的复发性卵巢癌患者被用来评估1997 ˜ 2010年肾脏疾病的发生情况。在Shaare Zedek医学中心，73例连续入组的卵巢癌患者被用来评估2002 ˜ 2010年肾脏疾病的发生情况。如果估算的肾小球滤过率（eGFR）< 60 mL/min/1.73 m2且持续时间> 3个月，并依据美国肾脏病基金会指南进行分期，患者诊断为CKD。 结果. 13例（23%）患者发生了分期≥3的CKD。3例患者肾活检显示有血栓性微血管病。 结论. CKD是目前接受化疗治疗的复发性卵巢癌患者潜在的长期并发症。 A retrospective review at two institutions was conducted to document the frequency and contributing factors to the emergence of chronic kidney disease among patients receiving long‐term treatment for recurrent ovarian cancer. A retrospective review at two institutions was conducted to document the frequency and contributing factors to the emergence of chronic kidney disease among patients receiving long-term treatment for recurrent ovarian cancer. After completing this course, the reader will be able to: Describe the need for additional vigilance regarding renal dysfunction when platinums, pegylated liposomal doxorubicin, bevacizumab, and gemcitabine are used for prolonged treatment of recurrent ovarian cancer in combination or sequentially following pre-existing renal damage.Describe and quantify the risk of chronic kidney disease in patients treated for ovarian cancer. This article is available for continuing medical education credit at CME.TheOncologist.com |
| Author | Michael, Jeffrey Rosengarten, Ora Kwa, Maryann Puzanov, Igor Gabizon, Alberto Shavit, Linda Kopolovic, Juri Baumgartner, Robert Muggia, Franco Barash, Irina Blank, Stephanie Curtin, John P. |
| Author_xml | – sequence: 1 givenname: Maryann surname: Kwa fullname: Kwa, Maryann – sequence: 2 givenname: Robert surname: Baumgartner fullname: Baumgartner, Robert – sequence: 3 givenname: Linda surname: Shavit fullname: Shavit, Linda – sequence: 4 givenname: Irina surname: Barash fullname: Barash, Irina – sequence: 5 givenname: Jeffrey surname: Michael fullname: Michael, Jeffrey – sequence: 6 givenname: Igor surname: Puzanov fullname: Puzanov, Igor – sequence: 7 givenname: Juri surname: Kopolovic fullname: Kopolovic, Juri – sequence: 8 givenname: Ora surname: Rosengarten fullname: Rosengarten, Ora – sequence: 9 givenname: Stephanie surname: Blank fullname: Blank, Stephanie – sequence: 10 givenname: John P. surname: Curtin fullname: Curtin, John P. – sequence: 11 givenname: Alberto surname: Gabizon fullname: Gabizon, Alberto – sequence: 12 givenname: Franco surname: Muggia fullname: Muggia, Franco email: franco.muggia@nyumc.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22622146$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUVtrFDEYDVKxF_0Lmkdfps09Mw8qZekNiltkBd9CJvvNbGQmWZPZyv57s3Qr1pf2IeTAd25wjtFBiAEQ-kDJKVVcnE0riMHFIfY-T6eMUFoRwdgrdESlaCrRkB8HBZOaV5rK5hAd5_yTkAI5e4MOGVOMUaGOUHuT8TcIdsCLVYpjGyfv8HnofVzbabXFNuCLEVLvQ4_vUmwHGLEPuOTjRQI7jRAmHDs8v7fJF_LMBgepWLpNSlBw_vIWve7skOHd_j9B3y8vFrPr6nZ-dTM7v62c1ERUVnYtZbBUykLHtZYgZU0cWA6utFbtUvG2FrTpiNPCivIkcU4tiRWtEg0_QZ8ffNebdoSlK82SHcw6-dGmrYnWm6eX4Femj_eGS1bzWhaDj3uDFH9tIE9m9NnBMNgAcZMNlZIqJnXdPE9lmtNGc0UK9f2_tf72edygED49EFyKOSfojPOTnXzctfSDocTsNjdPNje7zc1u86LX_-kfI55X7pN_-wG2L5WZ-dfZnEou-B-zJMwe |
| CitedBy_id | crossref_primary_10_1053_j_ajkd_2015_02_340 crossref_primary_10_1016_j_xkme_2025_100998 crossref_primary_10_1007_s13546_013_0718_3 crossref_primary_10_1038_ki_2013_408 crossref_primary_10_1177_1078155216628324 crossref_primary_10_1038_ki_2013_411 crossref_primary_10_1016_j_xkme_2022_100461 crossref_primary_10_1097_PAP_0000000000000122 crossref_primary_10_1007_s00280_020_04203_z crossref_primary_10_3389_fphar_2022_826908 crossref_primary_10_3390_medicina57060561 crossref_primary_10_1007_s00467_020_04800_3 crossref_primary_10_1053_j_ajkd_2023_08_014 crossref_primary_10_1016_j_tranon_2021_101081 crossref_primary_10_1053_j_ackd_2021_08_001 crossref_primary_10_1007_s40278_013_2652_6 crossref_primary_10_1016_j_nephro_2017_01_023 crossref_primary_10_1016_j_semnephrol_2023_151345 |
| Cites_doi | 10.1200/JCO.1995.13.7.1777 10.1001/jama.289.19.2560 10.7326/0003-4819-145-4-200608150-00004 10.2165/00003088-200342050-00002 10.1023/A:1008365716693 10.1002/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2 10.1016/j.ygyno.2008.09.034 10.1038/sj.ki.5002786 10.1056/NEJMoa0707330 10.1111/j.1440-1797.2010.01383.x 10.1056/NEJMra041842 10.1007/BF01612678 10.1016/j.tox.2006.05.013 10.1093/jnci/djq484 10.1200/JCO.1997.15.3.987 10.1053/j.seminoncol.2004.08.010 10.1093/annonc/mdl484 10.1046/j.1523-1755.2000.00342.x |
| ContentType | Journal Article |
| Copyright | 2012 AlphaMed Press AlphaMed Press 2012 |
| Copyright_xml | – notice: 2012 AlphaMed Press – notice: AlphaMed Press 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TO H94 5PM |
| DOI | 10.1634/theoncologist.2011-0422 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
| DatabaseTitleList | MEDLINE - Academic Oncogenes and Growth Factors Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1549-490X |
| EndPage | 1540 |
| ExternalDocumentID | PMC3528385 22622146 10_1634_theoncologist_2011_0422 ONCO1534 |
| Genre | article Multicenter Study Journal Article Case Reports |
| GroupedDBID | --- 0R~ 123 18M 1OC 2WC 36B 4.4 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAMMB AAPXW AAVAP AAWTL AAZKR ABEJV ABGNP ABPTD ABUWG ABXVV ACXQS ADBBV ADXAS AEFGJ AEGXH AENEX AFFHD AFKRA AFPKN AGXDD AIDQK AIDYY AJAOE ALMA_UNASSIGNED_HOLDINGS ALUQN AMNDL AOIJS BAWUL BENPR BFHJK CCPQU CS3 DCZOG DIK DU5 E3Z EBD EBS EJD EMB EMOBN F5P FRP FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE HZ~ IAO IHR INH ITC LUTES LYRES M1P O9- OK1 OVT P2P P2W PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO RAO RHI ROL RPM SUPJJ SV3 TOX TR2 UDS UKHRP W2D W8F WIN WOHZO WOQ WOW XSB ZZTAW AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7TO H94 5PM |
| ID | FETCH-LOGICAL-c5704-a5fb12ed66aef3775e5580cea3ec9326bd63b8419f0c74a474a50cc6d0a4b6493 |
| IEDL.DBID | WIN |
| ISICitedReferencesCount | 20 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000312923100009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1083-7159 1549-490X |
| IngestDate | Tue Nov 04 01:42:51 EST 2025 Sun Nov 09 14:41:45 EST 2025 Thu Oct 02 05:59:15 EDT 2025 Thu Apr 03 07:04:50 EDT 2025 Sat Nov 29 01:51:39 EST 2025 Tue Nov 18 20:55:45 EST 2025 Tue Nov 11 03:10:09 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5704-a5fb12ed66aef3775e5580cea3ec9326bd63b8419f0c74a474a50cc6d0a4b6493 |
| Notes | Sanofi, Roche, Imclone, Pfizer, GlaxoSmithKline, Lilly, Genentech (C/A); Lilly, Novartis, Sanofi, and Roche (H) Peter Harper Disclosures: Franco Muggia Johnson & Johnson (C/A). The other authors indicated no financial relationships. Reviewer “A”: BristolMeyers Squibb (IP); Ortho Biotech (H); Protea Biosciences (O) Section Editors Reviewer “B”: None None Dennis Chi Reviewer “C”: BiPar, Genentech, GlaxoSmithKline (C/A) ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3 ObjectType-Article-1 ObjectType-Feature-2 Section Editors: Dennis Chi: None; Peter Harper: Sanofi, Roche, Imclone, Pfizer, GlaxoSmithKline, Lilly, Genentech (C/A); Lilly, Novartis, Sanofi, and Roche (H) Disclosures: Franco Muggia: Johnson & Johnson (C/A). The other authors indicated no financial relationships. |
| OpenAccessLink | http://theoncologist.alphamedpress.org/content/17/12/1534.full.pdf |
| PMID | 22622146 |
| PQID | 1273197360 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3528385 proquest_miscellaneous_1551625789 proquest_miscellaneous_1273197360 pubmed_primary_22622146 crossref_citationtrail_10_1634_theoncologist_2011_0422 crossref_primary_10_1634_theoncologist_2011_0422 wiley_primary_10_1634_theoncologist_2011_0422_ONCO1534 |
| PublicationCentury | 2000 |
| PublicationDate | December 2012 |
| PublicationDateYYYYMMDD | 2012-12-01 |
| PublicationDate_xml | – month: 12 year: 2012 text: December 2012 |
| PublicationDecade | 2010 |
| PublicationPlace | Durham, NC, USA |
| PublicationPlace_xml | – name: Durham, NC, USA – name: United States |
| PublicationTitle | The oncologist (Dayton, Ohio) |
| PublicationTitleAlternate | Oncologist |
| PublicationYear | 2012 |
| Publisher | AlphaMed Press |
| Publisher_xml | – name: AlphaMed Press |
| References | 2007; 18 2002; 39 2012 1986; 77 1995; 13 2009; 112 1999; 85 2001; 29 2008; 73 2011; 16 2009; 27 1982; 46 2011; 103 2004; 351 2004; 31 1990; 116 2000; 58 2010; 28 1997; 15 2000; 11 2008; 358 2006; 225 2003; 289 2003; 42 2006; 145 Levey (2021122308235861900_B6) 2006; 145 Chobanian (2021122308235861900_B8) 2003; 289 Cannistra (2021122308235861900_B1) 2004; 351 Uziely (2021122308235861900_B3) 1995; 13 Bertani (2021122308235861900_B18) 1982; 46 Muggia (2021122308235861900_B12) 2009; 112 Muggia (2021122308235861900_B11) 2009; 27 Wang (2021122308235861900_B19) 2000; 58 Hirai (2021122308235861900_B21) 2006; 225 Muggia (2021122308235861900_B15) 1997; 15 Gabizon (2021122308235861900_B5) 2003; 42 Muggia (2021122308235861900_B2) 2011; 103 Pabla (2021122308235861900_B13) 2008; 73 Aghajanian (2021122308235861900_B23) 2001; 29 (2021122308235861900_B9) 2012 Andreopoulou (2021122308235861900_B4) 2007; 18 National Kidney Foundation (2021122308235861900_B7) 2002; 39 Metz-Kurschel (2021122308235861900_B14) 1990; 116 Lee (2021122308235861900_B20) 2011; 16 Alberts (2021122308235861900_B16) 2004; 31 Gabizon (2021122308235861900_B22) 1986; 77 Fung (2021122308235861900_B25) 1999; 85 Eremina (2021122308235861900_B24) 2008; 358 Safra (2021122308235861900_B10) 2000; 11 Safra (2021122308235861900_B17) 2010; 28 11904577 - Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 18977023 - Gynecol Oncol. 2009 Jan;112(1):275-81 6172662 - Lab Invest. 1982 Jan;46(1):16-23 11012915 - Kidney Int. 2000 Oct;58(4):1797-804 18337603 - N Engl J Med. 2008 Mar 13;358(11):1129-36 2182639 - J Cancer Res Clin Oncol. 1990;116(2):203-6 11038041 - Ann Oncol. 2000 Aug;11(8):1029-33 18272962 - Kidney Int. 2008 May;73(9):994-1007 21175974 - Nephrology (Carlton). 2011 Jan;16(1):30-8 15717738 - Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90 16908915 - Ann Intern Med. 2006 Aug 15;145(4):247-54 10223245 - Cancer. 1999 May 1;85(9):2023-32 3461207 - J Natl Cancer Inst. 1986 Aug;77(2):459-69 22529265 - J Clin Oncol. 2012 Jun 10;30(17):2039-45 21115880 - J Natl Cancer Inst. 2011 Jan 19;103(2):160-1 7602367 - J Clin Oncol. 1995 Jul;13(7):1777-85 12739982 - Clin Pharmacokinet. 2003;42(5):419-36 15590954 - N Engl J Med. 2004 Dec 9;351(24):2519-29 12748199 - JAMA. 2003 May 21;289(19):2560-72 9060537 - J Clin Oncol. 1997 Mar;15(3):987-93 16870316 - Toxicology. 2006 Aug 15;225(2-3):81-9 17301073 - Ann Oncol. 2007 Apr;18(4):716-21 |
| References_xml | – volume: 29 year: 2001 article-title: OCEANS: A randomized, double‐blinded, placebo‐controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum‐sensitive recurrent epithelial ovarian cancer (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) publication-title: J Clin Oncol – volume: 145 start-page: 247 year: 2006 end-page: 254 article-title: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate publication-title: Ann Intern Med – volume: 15 start-page: 987 year: 1997 end-page: 993 article-title: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation publication-title: J Clin Oncol – volume: 289 start-page: 2560 year: 2003 end-page: 2572 article-title: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report publication-title: JAMA – volume: 42 start-page: 419 year: 2003 end-page: 436 article-title: Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies publication-title: Clin Pharmacokinet – volume: 39 start-page: S1 issue: suppl 1 year: 2002 end-page: S266 article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification publication-title: Am J Kidney Dis – volume: 28 issue: 15 suppl year: 2010 article-title: Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations publication-title: J Clin Oncol – volume: 16 start-page: 30 year: 2011 end-page: 38 article-title: Adriamycin nephropathy: A model of focal segmental glomerulosclerosis publication-title: Nephrology (Carlton) – volume: 77 start-page: 459 year: 1986 end-page: 469 article-title: Comparative long‐term study of the toxicities of free and liposome‐associated doxorubicin in mice after intravenous administration publication-title: J Natl Cancer Inst – volume: 11 start-page: 1029 year: 2000 end-page: 1033 article-title: Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m publication-title: Ann Oncol – volume: 85 start-page: 2023 year: 1999 end-page: 2032 article-title: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy publication-title: Cancer – year: 2012 – volume: 13 start-page: 1777 year: 1995 end-page: 1785 article-title: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies publication-title: J Clin Oncol – volume: 351 start-page: 2519 year: 2004 end-page: 2529 article-title: Cancer of the ovary publication-title: N Engl J Med – volume: 116 start-page: 203 year: 1990 end-page: 206 article-title: Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin publication-title: J Cancer Res Clin Oncol – volume: 31 start-page: 53 issue: suppl 13 year: 2004 end-page: 90 article-title: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials publication-title: Semin Oncol – volume: 103 start-page: 160 year: 2011 end-page: 161 article-title: Delayed neoplastic and renal complications in women receiving long‐term chemotherapy for recurrent ovarian cancer publication-title: J Natl Cancer Inst – volume: 358 start-page: 1129 year: 2008 end-page: 1136 article-title: VEGF inhibition and renal thrombotic microangiopathy publication-title: N Engl J Med – volume: 46 start-page: 16 year: 1982 end-page: 23 article-title: Adriamycin‐induced nephrotic syndrome in rats: Sequence of pathologic events publication-title: Lab Invest – volume: 73 start-page: 994 year: 2008 end-page: 1007 article-title: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies publication-title: Kidney Int – volume: 27 issue: 15 suppl year: 2009 article-title: Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second‐line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results publication-title: J Clin Oncol – volume: 225 start-page: 81 year: 2006 end-page: 89 article-title: Upregulation of renal eNOS by high‐sodium diet facilitates hypertension in doxorubicin‐treated rats through enhanced oxidative stress publication-title: Toxicology – volume: 112 start-page: 275 year: 2009 end-page: 281 article-title: Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer publication-title: Gynecol Oncol – volume: 18 start-page: 716 year: 2007 end-page: 721 article-title: Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): Experience with long‐term maintenance in responding patients with recurrent epithelial ovarian cancer publication-title: Ann Oncol – volume: 58 start-page: 1797 year: 2000 end-page: 1804 article-title: Progressive Adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events publication-title: Kidney Int – volume: 29 year: 2001 ident: 2021122308235861900_B23 article-title: OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC) publication-title: J Clin Oncol – volume: 39 start-page: S1 issue: suppl 1 year: 2002 ident: 2021122308235861900_B7 article-title: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification publication-title: Am J Kidney Dis – volume: 13 start-page: 1777 year: 1995 ident: 2021122308235861900_B3 article-title: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies publication-title: J Clin Oncol doi: 10.1200/JCO.1995.13.7.1777 – volume-title: PDR.net. Doxil (doxorubicin hcl liposome) year: 2012 ident: 2021122308235861900_B9 – volume: 289 start-page: 2560 year: 2003 ident: 2021122308235861900_B8 article-title: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report publication-title: JAMA doi: 10.1001/jama.289.19.2560 – volume: 145 start-page: 247 year: 2006 ident: 2021122308235861900_B6 article-title: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate publication-title: Ann Intern Med doi: 10.7326/0003-4819-145-4-200608150-00004 – volume: 42 start-page: 419 year: 2003 ident: 2021122308235861900_B5 article-title: Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies publication-title: Clin Pharmacokinet doi: 10.2165/00003088-200342050-00002 – volume: 27 issue: 15 suppl year: 2009 ident: 2021122308235861900_B11 article-title: Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results publication-title: J Clin Oncol – volume: 11 start-page: 1029 year: 2000 ident: 2021122308235861900_B10 article-title: Pegylated liposomal doxorubicin (Doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 publication-title: Ann Oncol doi: 10.1023/A:1008365716693 – volume: 85 start-page: 2023 year: 1999 ident: 2021122308235861900_B25 article-title: A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy publication-title: Cancer doi: 10.1002/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2 – volume: 112 start-page: 275 year: 2009 ident: 2021122308235861900_B12 article-title: Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.09.034 – volume: 73 start-page: 994 year: 2008 ident: 2021122308235861900_B13 article-title: Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies publication-title: Kidney Int doi: 10.1038/sj.ki.5002786 – volume: 358 start-page: 1129 year: 2008 ident: 2021122308235861900_B24 article-title: VEGF inhibition and renal thrombotic microangiopathy publication-title: N Engl J Med doi: 10.1056/NEJMoa0707330 – volume: 16 start-page: 30 year: 2011 ident: 2021122308235861900_B20 article-title: Adriamycin nephropathy: A model of focal segmental glomerulosclerosis publication-title: Nephrology (Carlton) doi: 10.1111/j.1440-1797.2010.01383.x – volume: 351 start-page: 2519 year: 2004 ident: 2021122308235861900_B1 article-title: Cancer of the ovary publication-title: N Engl J Med doi: 10.1056/NEJMra041842 – volume: 116 start-page: 203 year: 1990 ident: 2021122308235861900_B14 article-title: Investigations on the acute and chronic nephrotoxicity of the new platinum analogue carboplatin publication-title: J Cancer Res Clin Oncol doi: 10.1007/BF01612678 – volume: 225 start-page: 81 year: 2006 ident: 2021122308235861900_B21 article-title: Upregulation of renal eNOS by high-sodium diet facilitates hypertension in doxorubicin-treated rats through enhanced oxidative stress publication-title: Toxicology doi: 10.1016/j.tox.2006.05.013 – volume: 28 issue: 15 suppl year: 2010 ident: 2021122308235861900_B17 article-title: Pegylated liposomal doxorubicin (PLD) treatment for recurrent epithelial ovarian cancer (rEOC): Implications of BRCA mutations publication-title: J Clin Oncol – volume: 46 start-page: 16 year: 1982 ident: 2021122308235861900_B18 article-title: Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events publication-title: Lab Invest – volume: 77 start-page: 459 year: 1986 ident: 2021122308235861900_B22 article-title: Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration publication-title: J Natl Cancer Inst – volume: 103 start-page: 160 year: 2011 ident: 2021122308235861900_B2 article-title: Delayed neoplastic and renal complications in women receiving long-term chemotherapy for recurrent ovarian cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq484 – volume: 15 start-page: 987 year: 1997 ident: 2021122308235861900_B15 article-title: Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.3.987 – volume: 31 start-page: 53 issue: suppl 13 year: 2004 ident: 2021122308235861900_B16 article-title: Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials publication-title: Semin Oncol doi: 10.1053/j.seminoncol.2004.08.010 – volume: 18 start-page: 716 year: 2007 ident: 2021122308235861900_B4 article-title: Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdl484 – volume: 58 start-page: 1797 year: 2000 ident: 2021122308235861900_B19 article-title: Progressive Adriamycin nephropathy in mice: Sequence of histologic and immunohistochemical events publication-title: Kidney Int doi: 10.1046/j.1523-1755.2000.00342.x – reference: 10223245 - Cancer. 1999 May 1;85(9):2023-32 – reference: 12748199 - JAMA. 2003 May 21;289(19):2560-72 – reference: 7602367 - J Clin Oncol. 1995 Jul;13(7):1777-85 – reference: 6172662 - Lab Invest. 1982 Jan;46(1):16-23 – reference: 12739982 - Clin Pharmacokinet. 2003;42(5):419-36 – reference: 3461207 - J Natl Cancer Inst. 1986 Aug;77(2):459-69 – reference: 21175974 - Nephrology (Carlton). 2011 Jan;16(1):30-8 – reference: 15590954 - N Engl J Med. 2004 Dec 9;351(24):2519-29 – reference: 18272962 - Kidney Int. 2008 May;73(9):994-1007 – reference: 21115880 - J Natl Cancer Inst. 2011 Jan 19;103(2):160-1 – reference: 11038041 - Ann Oncol. 2000 Aug;11(8):1029-33 – reference: 16908915 - Ann Intern Med. 2006 Aug 15;145(4):247-54 – reference: 15717738 - Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90 – reference: 2182639 - J Cancer Res Clin Oncol. 1990;116(2):203-6 – reference: 11904577 - Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266 – reference: 16870316 - Toxicology. 2006 Aug 15;225(2-3):81-9 – reference: 18337603 - N Engl J Med. 2008 Mar 13;358(11):1129-36 – reference: 22529265 - J Clin Oncol. 2012 Jun 10;30(17):2039-45 – reference: 11012915 - Kidney Int. 2000 Oct;58(4):1797-804 – reference: 18977023 - Gynecol Oncol. 2009 Jan;112(1):275-81 – reference: 9060537 - J Clin Oncol. 1997 Mar;15(3):987-93 – reference: 17301073 - Ann Oncol. 2007 Apr;18(4):716-21 |
| SSID | ssj0015932 |
| Score | 2.1724584 |
| Snippet | Learning Objectives
After completing this course, the reader will be able to:
Describe the need for additional vigilance regarding renal dysfunction when... Ovarian cancer is usually diagnosed at an advanced stage, with most patients undergoing surgery followed by platinum- and taxane-based chemotherapy. After... A retrospective review at two institutions was conducted to document the frequency and contributing factors to the emergence of chronic kidney disease among... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1534 |
| SubjectTerms | Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Bevacizumab Chronic kidney disease Creatinine - blood Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Fatal Outcome Female Gynecologic Oncology Humans Middle Aged Ovarian cancer Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Pegylated liposomal doxorubicin Platinum - therapeutic use Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Quality of Life Recurrence Renal Insufficiency, Chronic - etiology Renal Insufficiency, Chronic - pathology Renal thrombotic microangiopathy Retrospective Studies Risk Factors Taxoids - therapeutic use Thrombosis - etiology Thrombosis - pathology Topotecan - administration & dosage Topotecan - adverse effects |
| Title | Is Renal Thrombotic Angiopathy an Emerging Problem in the Treatment of Ovarian Cancer Recurrences? |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2011-0422 https://www.ncbi.nlm.nih.gov/pubmed/22622146 https://www.proquest.com/docview/1273197360 https://www.proquest.com/docview/1551625789 https://pubmed.ncbi.nlm.nih.gov/PMC3528385 |
| Volume | 17 |
| WOSCitedRecordID | wos000312923100009&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVASL databaseName: Oxford Journals Open Access (Activated by CARLI) customDbUrl: eissn: 1549-490X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: TOX dateStart: 19960101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1549-490X dateEnd: 20211231 omitProxy: false ssIdentifier: ssj0015932 issn: 1083-7159 databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9aiviitlY9P0oKvq7NXj73ScphsVDvipx6b0uSzbUHmpW7tuB_70yyt3gUP5A-7MLuThIymZlMMtnfEPJaIho1t6EobeMLYSwrjHdgDIXnsrGa-wRW_flUj8dmNqvOOkgh_Bcm40P0G26oGcleo4Jbl7OQKC5gEPFHv5iQnYEfb_JWnxiiNS5FUtEvJ-M-niArnuOehhcanrqTXlDT4W_q2ZynbjifN89Q_urbpsnp-OEtdusRedB5qPQoi9QOuRPiLrn3oYvBPybuZEU_BiSZXizbb64FOnoUzxctZjf-QW2kuNOFyY_oWU5XQxeRQot0uj7VTts5nVzDMh2IRyh3S6jSJ6gosFtv98in43fT0fuiy9RQeKmZKKycu3IYGqVsmHOtZZDSMB8sDx4dRNco7owoqznzWlgBl2Teq4ZZ4ZSo-BOyFdsYnhFahsAVguU2rhENK60P2rlKeKGNlDIMiFqPS-07GHPMpvG1xuUM8LDe4GCNHKyRgwPC-oLfM5LH34scrAe-Bq3DUIqNob1a1SV4fWWluWJ_oMEYJFrEakCeZmHpGwand4gp1QdEb4hRT4Co35tf4uIioX8nOB4jgQ9JjP61L_VkPJrA9Cae_2_BF-Q-vBzmszwvydbl8iq8Itv--nKxWu6Tu3pm4D6dzPaT7v0ENxM5Rg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQQLAXxjeFAUbiNeDUX8kTmqpNq-jSCRW0N8t23K0SOFO7TeK_585Jo1UTH0I85CHK2ZHPd-ez7_w7Qt5JRKPmNmS5rX0mCsuywjswhsJzWVvNfQKr_jrRVVWcnJTHXf4T3oVp8SH6AzfUjGSvUcHxQDppueICZhFv-sUE7QwMed-e9YkhmOPbQoEfj7dLxlUfUZAlbyOfBc80vHW5XtDVh190tLlS3XA_b2ZRXvdu0_J0sPM_B_aA3O-cVLrXStVDcivER-TuUReGf0zceEU_BySZnS2b764BOroXTxcNFjj-QW2keNiF9Y_ocVuxhi4ihT_S2TqxnTZzOr2CnToQj1D0ltClT2hRYLo-PiFfDvZno8OsK9aQeamZyKycu3wYaqVsmHOtZZCyYD5YHjz6iK5W3BUiL-fMa2EFPJJ5r2pmhYP54k_JVmxieE5oHgJXiJdbu1rULLc-aOdK4YUupJRhQNR6YozvkMyxoMY3gzsa4KHZ4KBBDhrk4ICwvuF5C-bx5yZv1zNvQPEwmmJjaC5XJgfHLy81V-w3NBiGRKNYDsizVlr6H4PfO8Sq6gOiN-SoJ0Dg780vcXGWAMATIk8hgQ9Jjv52LGZajaawwokX_9rwDbl3ODuamMm4-vSSbAPBsE3t2SVbF8vL8Irc8VcXi9XydVK-nxf7O3I |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Zj9MwELbQgla8cB_lNBKvgaS-kie0KlRULGmFCto3y1d2K4GzandX4t8z46QR1YpDiIc8RB7bynhmPPGMvyHkpUA0amZCVhjvMl6aPCudBWPIHRPeKOYSWPWXQ1XX5dFRtejzn_AuTIcPMRy4oWYke40KHk59k7RcMg6riDf9YoJ2Boa86s76-BjM8VUuYSPE2yWzeogoiIp1kc-SZQre-lwvGOr1Lwba3akuuZ-Xsyh_9m7T9jS9-T8_7Ba50Tup9KCTqtvkSoh3yP7HPgx_l9jZhn4KSLI8WbffbAt09CAer1oscPydmkjxsAvrH9FFV7GGriKFGelym9hO24bOL-BPHYgnKHprGNIltCgwXW_ukc_Td8vJ-6wv1pA5oXKeGdHYYhy8lCY0TCkRhChzFwwLDn1E6yWzJS-qJneKGw6PyJ2TPjfcSl6x-2QvtjE8JLQIgUnEy_XWc58XxgVlbcUdV6UQIoyI3C6Mdj2SORbU-KrxjwZ4qHc4qJGDGjk4IvnQ8bQD8_hzlxfbldegeBhNMTG05xtdgONXVIrJ_Dc0GIZEo1iNyINOWoaJwe8dY1X1EVE7cjQQIPD3bktcnSQA8ITIUwrgQ5Kjv_0WPa8nc9jh-KN_7fic7C_eTvXhrP7wmFyH9nGX2fOE7J2tz8NTcs1dnK0262dJ934AMeM65A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Is+Renal+Thrombotic+Angiopathy+an+Emerging+Problem+in+the+Treatment+of+Ovarian+Cancer+Recurrences%3F&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Kwa%2C+Maryann&rft.au=Baumgartner%2C+Robert&rft.au=Shavit%2C+Linda&rft.au=Barash%2C+Irina&rft.date=2012-12-01&rft.pub=AlphaMed+Press&rft.issn=1083-7159&rft.eissn=1549-490X&rft.volume=17&rft.issue=12&rft.spage=1534&rft.epage=1540&rft_id=info:doi/10.1634%2Ftheoncologist.2011-0422&rft.externalDBID=10.1634%252Ftheoncologist.2011-0422&rft.externalDocID=ONCO1534 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon |